QQQ   431.77 (+0.16%)
AAPL   169.38 (-1.92%)
MSFT   416.03 (+0.58%)
META   502.05 (+0.36%)
GOOGL   154.65 (-0.14%)
AMZN   183.75 (+0.07%)
TSLA   156.93 (-2.82%)
NVDA   872.21 (+1.42%)
AMD   163.28 (+1.85%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.05 (-1.17%)
F   12.16 (-0.57%)
MU   121.30 (-0.06%)
GE   155.76 (+1.34%)
CGC   6.88 (-1.43%)
DIS   114.11 (+1.03%)
AMC   2.72 (+10.12%)
PFE   25.84 (-0.27%)
PYPL   63.96 (+0.71%)
XOM   118.78 (-0.75%)
QQQ   431.77 (+0.16%)
AAPL   169.38 (-1.92%)
MSFT   416.03 (+0.58%)
META   502.05 (+0.36%)
GOOGL   154.65 (-0.14%)
AMZN   183.75 (+0.07%)
TSLA   156.93 (-2.82%)
NVDA   872.21 (+1.42%)
AMD   163.28 (+1.85%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.05 (-1.17%)
F   12.16 (-0.57%)
MU   121.30 (-0.06%)
GE   155.76 (+1.34%)
CGC   6.88 (-1.43%)
DIS   114.11 (+1.03%)
AMC   2.72 (+10.12%)
PFE   25.84 (-0.27%)
PYPL   63.96 (+0.71%)
XOM   118.78 (-0.75%)
QQQ   431.77 (+0.16%)
AAPL   169.38 (-1.92%)
MSFT   416.03 (+0.58%)
META   502.05 (+0.36%)
GOOGL   154.65 (-0.14%)
AMZN   183.75 (+0.07%)
TSLA   156.93 (-2.82%)
NVDA   872.21 (+1.42%)
AMD   163.28 (+1.85%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.05 (-1.17%)
F   12.16 (-0.57%)
MU   121.30 (-0.06%)
GE   155.76 (+1.34%)
CGC   6.88 (-1.43%)
DIS   114.11 (+1.03%)
AMC   2.72 (+10.12%)
PFE   25.84 (-0.27%)
PYPL   63.96 (+0.71%)
XOM   118.78 (-0.75%)
QQQ   431.77 (+0.16%)
AAPL   169.38 (-1.92%)
MSFT   416.03 (+0.58%)
META   502.05 (+0.36%)
GOOGL   154.65 (-0.14%)
AMZN   183.75 (+0.07%)
TSLA   156.93 (-2.82%)
NVDA   872.21 (+1.42%)
AMD   163.28 (+1.85%)
NIO   3.81 (-2.06%)
BABA   69.89 (-1.03%)
T   16.05 (-1.17%)
F   12.16 (-0.57%)
MU   121.30 (-0.06%)
GE   155.76 (+1.34%)
CGC   6.88 (-1.43%)
DIS   114.11 (+1.03%)
AMC   2.72 (+10.12%)
PFE   25.84 (-0.27%)
PYPL   63.96 (+0.71%)
XOM   118.78 (-0.75%)
NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Stock Price, News & Analysis

$1.14
-0.01 (-0.44%)
(As of 12:42 PM ET)
Today's Range
$1.02
$1.14
50-Day Range
$1.05
$1.79
52-Week Range
$0.47
$1.83
Volume
462,804 shs
Average Volume
354,244 shs
Market Capitalization
$39.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.30

Unicycive Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
377.5% Upside
$5.30 Price Target
Short Interest
Healthy
1.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of Unicycive Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

518th out of 930 stocks

Pharmaceutical Preparations Industry

239th out of 429 stocks

UNCY stock logo

About Unicycive Therapeutics Stock (NASDAQ:UNCY)

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

UNCY Stock Price History

UNCY Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Unicycive Announces $50 Million Private Placement
See More Headlines
Receive UNCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/16/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UNCY
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.30
High Stock Price Target
$9.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+377.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-30,540,000.00
Pretax Margin
-4,525.04%

Debt

Sales & Book Value

Annual Sales
$680,000.00
Book Value
($0.11) per share

Miscellaneous

Free Float
20,158,000
Market Cap
$38.58 million
Optionable
Not Optionable
Beta
2.66
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Shalabh K. Gupta M.D. (Age 51)
    MPA, Founder, Chairman, CEO & President
    Comp: $1.46M
  • Dr. Pramod Gupta Ph.D. (Age 64)
    Executive Vice President of Pharmaceutical & Business Operations
    Comp: $779.18k
  • Mr. Douglas Jermasek M.B.A. (Age 62)
    Executive Vice President of Corporate Strategy
    Comp: $430.81k
  • Mr. John W. Townsend CPA (Age 62)
    Chief Financial Officer
    Comp: $197.86k

UNCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Unicycive Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" UNCY shares.
View UNCY analyst ratings
or view top-rated stocks.

What is Unicycive Therapeutics' stock price target for 2024?

4 brokers have issued 12-month price objectives for Unicycive Therapeutics' shares. Their UNCY share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $5.30 in the next twelve months. This suggests a possible upside of 377.5% from the stock's current price.
View analysts price targets for UNCY
or view top-rated stocks among Wall Street analysts.

How have UNCY shares performed in 2024?

Unicycive Therapeutics' stock was trading at $0.8677 at the beginning of 2024. Since then, UNCY stock has increased by 27.9% and is now trading at $1.11.
View the best growth stocks for 2024 here
.

Are investors shorting Unicycive Therapeutics?

Unicycive Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 256,800 shares, an increase of 352.9% from the March 15th total of 56,700 shares. Based on an average daily volume of 357,100 shares, the short-interest ratio is currently 0.7 days. Approximately 1.0% of the shares of the company are short sold.
View Unicycive Therapeutics' Short Interest
.

When is Unicycive Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our UNCY earnings forecast
.

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) issued its earnings results on Thursday, March, 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02.

When did Unicycive Therapeutics IPO?

Unicycive Therapeutics (UNCY) raised $25 million in an IPO on Tuesday, July 13th 2021. The company issued 4,600,000 shares at a price of $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UNCY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners